Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
Elevated baseline erythropoietin levels may serve as a serologic marker to predict which patients with advanced heart failure will benefit from cardiac resynchronization therapy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Alexander et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: